Fate Therapeutics Nabs $9.24M to Help Combat Blood Cancer
August 27, 2012
Fate Therapeutics, developer of stem-cell treatments, has raised $9.24 million in venture funding to continue its work on treatments for use in blood-cancer patients. Its most advanced treatment, ProHema, is currently in clinical trials for blood-cancer patients who are receiving stem-cell transplants. San Diego-based Fate Therapeutics has raised $58.2 million since it was founded in 2007.